Aptorum Group Ltd Class A (APM) - Net Assets

Latest as of December 2025: $13.79 Million USD

Based on the latest financial reports, Aptorum Group Ltd Class A (APM) has net assets worth $13.79 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($18.69 Million) and total liabilities ($4.90 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Aptorum Group Ltd Class A asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets $13.79 Million
% of Total Assets 73.79%
Annual Growth Rate -6.44%
5-Year Change -21.22%
10-Year Change N/A
Growth Volatility 68.97

Aptorum Group Ltd Class A - Net Assets Trend (2016–2025)

This chart illustrates how Aptorum Group Ltd Class A's net assets have evolved over time, based on quarterly financial data. Also explore APM total assets for the complete picture of this company's asset base.

Annual Net Assets for Aptorum Group Ltd Class A (2016–2025)

The table below shows the annual net assets of Aptorum Group Ltd Class A from 2016 to 2025. For live valuation and market cap data, see Aptorum Group Ltd Class A (APM) market capitalisation.

Year Net Assets Change
2025-12-31 $13.79 Million +17.11%
2024-12-31 $11.78 Million -23.44%
2023-12-31 $15.38 Million +96.38%
2022-12-31 $7.83 Million -55.25%
2021-12-31 $17.51 Million -54.12%
2020-12-31 $38.15 Million +156.89%
2019-12-31 $14.85 Million -54.65%
2018-12-31 $32.75 Million +8.33%
2017-12-31 $30.23 Million +20.36%
2016-12-31 $25.11 Million --

Equity Component Analysis

This analysis shows how different components contribute to Aptorum Group Ltd Class A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 2403.8% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock $80.00 0.00%
Other Comprehensive Income $-92.31K -0.40%
Other Components $97.00 Million 419.64%
Total Equity $23.12 Million 100.00%

Aptorum Group Ltd Class A Competitors by Market Cap

The table below lists competitors of Aptorum Group Ltd Class A ranked by their market capitalization.

Company Market Cap
Vivesto AB
ST:VIVE
$5.59 Million
Bang Overseas Limited
NSE:BANG
$5.59 Million
Linkage Global Inc Ordinary Shares
NASDAQ:LGCB
$5.59 Million
Hydrofarm Holdings Group Inc
NASDAQ:HYFM
$5.59 Million
JPMorgan Indian Inv Trust
LSE:JII
$5.58 Million
Masivo Silver Corp
V:MASS
$5.58 Million
Destiny Media Technologies Inc
V:DSY
$5.58 Million
Mitra International Resources
JK:MIRA
$5.57 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Aptorum Group Ltd Class A's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 21,134,514 to 23,115,160, a change of 1,980,646 (9.4%).
  • Net loss of 1,363,270 reduced equity.
  • New share issuances of 5,070,000 increased equity.
  • Other comprehensive income decreased equity by 181,472.
  • Other factors decreased equity by 1,544,612.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $-1.36 Million -5.9%
Share Issuances $5.07 Million +21.93%
Other Comprehensive Income $-181.47K -0.79%
Other Changes $-1.54 Million -6.68%
Total Change $- 9.37%

Book Value vs Market Value Analysis

This analysis compares Aptorum Group Ltd Class A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.28x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has increased from 0.09x to 0.28x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 $10.04 $0.88 x
2018-12-31 $11.86 $0.88 x
2019-12-31 $5.64 $0.88 x
2020-12-31 $13.27 $0.88 x
2021-12-31 $6.74 $0.88 x
2022-12-31 $4.40 $0.88 x
2023-12-31 $5.50 $0.88 x
2024-12-31 $3.88 $0.88 x
2025-12-31 $3.14 $0.88 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Aptorum Group Ltd Class A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -5.90%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 0.81x
  • Recent ROE (-5.90%) is above the historical average (-36.50%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2016 -8.50% 0.00% 0.00x 1.01x $-4.65 Million
2017 -8.42% 0.00% 0.00x 1.04x $-5.57 Million
2018 -44.79% -3868.04% 0.01x 1.36x $-18.14 Million
2019 -114.22% -3491.81% 0.02x 1.46x $-20.32 Million
2020 16.89% 775.31% 0.02x 1.06x $2.88 Million
2021 -106.10% -1624.38% 0.07x 0.93x $-27.41 Million
2022 -62.37% -756.17% 0.06x 1.33x $-11.37 Million
2023 -11.37% -654.88% 0.02x 0.83x $-5.31 Million
2024 -20.19% 0.00% 0.00x 0.76x $-6.38 Million
2025 -5.90% 0.00% 0.00x 0.81x $-3.67 Million

Industry Comparison

This section compares Aptorum Group Ltd Class A's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $44,828,400
  • Average return on equity (ROE) among peers: -124.18%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Aptorum Group Ltd Class A (APM) $13.79 Million -8.50% 0.36x $5.59 Million
Aardvark Therapeutics, Inc. Common Stock (AARD) $-54.64 Million 0.00% 0.00x $118.88 Million
Abcellera Biologics Inc (ABCL) $10.25 Million -21.57% 1.29x $1.07 Billion
Abeona Therapeutics Inc (ABEO) $3.60 Million -91.89% 0.28x $292.09 Million
Acumen Pharmaceuticals Inc (ABOS) $266.97 Million -19.62% 0.16x $171.87 Million
Abpro Holdings, Inc. (ABP) $3.07 Million -479.81% 1.57x $448.19K
Absci Corp (ABSI) $67.00 Million -21.42% 0.32x $345.85 Million
Arbutus Biopharma Corp (ABUS) $88.00 Million -44.09% 0.34x $840.56 Million
ABVC Biopharma Inc (ABVC) $80.00K -31.70% 0.38x $26.41 Million
Abivax SA American Depositary Shares (ABVX) $40.58 Million -434.26% 4.06x $9.33 Billion
ACADIA Pharmaceuticals Inc (ACAD) $23.36 Million -97.44% 0.37x $3.74 Billion

About Aptorum Group Ltd Class A

NASDAQ:APM USA Biotechnology
Market Cap
$5.59 Million
Market Cap Rank
#28139 Global
#5545 in USA
Share Price
$0.88
Change (1 day)
+0.57%
52-Week Range
$0.74 - $4.25
All Time High
$325.50
About

Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small mol… Read more